Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.Mos4.HIV, MVA-BN-HIV and bNAbs in HIV-1-Infected Adults on Suppressive ART
NCT04983030Phase 2Completed
- Start
- Apr 2022
- Primary completion
- Feb 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ad26.Mos4.HIV, MVA-mBN32, PGT121, PGDM1400LS and VRC07-523LS in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoints: Percentage of Participants With Solicited Local Adverse Events, Percentage of Participants With Solicited Systemic Adverse Events and 5 more. Started Apr 2022; status: completed.
02
Drugs
Ad26.Mos4.HIVMVA-mBN32PGT121PGDM1400LSVRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04983030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983030.